Combination lipid-lowering therapy as first-line strategy in very high-risk patients-Reference-Cited by-同舟云学术

Combination lipid-lowering therapy as first-line strategy in very high-risk patients

Published:2021-10-12 Issue: Volume: Page:
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Ray Kausik K¹,Reeskamp Laurens F²^ORCID,Laufs Ulrich³^ORCID,Banach Maciej⁴^ORCID,Mach François⁵^ORCID,Tokgözoğlu Lale S⁶^ORCID,Connolly Derek L⁷,Gerrits Anja J⁸,Stroes Erik S G²^ORCID,Masana Luis⁹^ORCID,Kastelein John J P²^ORCID

Affiliation:

1. Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College London, The Reynolds Building, St Dunstan's Road, London W6 8RP, UK

2. Department of Vascular Medicine, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Meibergdreef 9, Amsterdam 1105AZ, the Netherlands

3. Clinic and Policlinic for Cardiology, University Hospital Leipzig, Liebigstraße 20, Leipzig 04103, Germany

4. Department of Hypertension, Medical University of Lodz, Zeromskiego 113, Lodz 90-549, Poland

5. Department of Cardiology, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, Switzerland

6. Department of Cardiology, Hacettepe University Faculty of Medicine, 06100 Sıhhiye, Ankara, Turkey

7. Department of Cardiology, Sandwell and West Birmingham Hospitals NHS Trust Birmingham, Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

8. MEDCON International, Adriaan Pauwlaan 29, Heemstede 2101 AJ, the Netherlands

9. Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV CIBERDEM, Reus 43201, Spain

Funder

Amgen and Sanofi

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehab718/40572334/ehab718.pdf

Reference15 articles.

1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017

2. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials;Gencer;Lancet,2020

3. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease;Ference;J Am Coll Cardiol,2012